Summary

Telmisartan did not reduce the primary composite of cardiovascular death, myocardial infarction, stroke, or hospitalization for heart failure in patients with diabetes or high-risk vascular disease who are unable to tolerate standard treatment with angiotensin-converting enzyme inhibitors, according to findings from the Telmisartan Randomized AssessmeNt Study in aCE iNtolerant subjects with cardiovascular Disease [TRANSCEND; NCT00153101] Trial.